Is Cellectar Biosciences Inc (NASDAQ: CLRB) Worth What Its Shareholders Think It Is?

During the last session, Cellectar Biosciences Inc (NASDAQ:CLRB)’s traded shares were 1.09 million, with the beta value of the company hitting 0.99. The 52-week high for the CLRB share is $4.45, that puts it down -1434.48 from that peak though still a striking 24.14% gain since the share price plummeted to a 52-week low of $0.22. The company’s market capitalization is $13.24M, and the average intraday trading volume over the past 10 days was 1.63 million shares, and the average trade volume was 2.76 million shares over the past three months.

Cellectar Biosciences Inc (CLRB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.50. CLRB has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.

Cellectar Biosciences Inc (NASDAQ:CLRB) trade information

Cellectar Biosciences Inc (CLRB) registered a -0.21% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.21% in intraday trading to $0.29, hitting a weekly high. The stock’s 5-day price performance is 9.86%, and it has moved by 1.99% in 30 days. Based on these gigs, the overall price performance for the year is -91.79%. The short interest in Cellectar Biosciences Inc (NASDAQ:CLRB) is 1.84 million shares and it means that shorts have 8.34 day(s) to cover.

The consensus price target of analysts on Wall Street is $12, which implies an increase of 97.58% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $12 respectively. As a result, CLRB is trading at a discount of -4037.93% off the target high and -4037.93% off the low.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 41.77%. While earnings are projected to return 48.15% in 2025, the next five years will return 32.07% per annum.

CLRB Dividends

Cellectar Biosciences Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.